Latest news with #Abreva
Associated Press
10-04-2025
- Health
- Associated Press
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Ruvidar TM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 ('HSV-1") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. TM (1%). To view an enhanced version of this graphic, please visit: Figure 2. Abreva (10% Docosanol) (6 days of treatment x 5 times per day) To view an enhanced version of this graphic, please visit: Figure 3. Ruvidar TM (1%) (5 days of treatment x once per day) To view an enhanced version of this graphic, please visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., Research Scientist, Theralase®, who conducted the preclinical study stated, " I have now had the opportunity to conduct my next set of experiments, where I increased the number of daily applications of Acyclovir (5%) and Abreva (10% Docosanol) from once per day to 5 times daily for 5 and 6 days, respectively. In this set of experiments, Ruvidar TM (1%) remained at once daily for 5 days. As can be clearly seen from the photographs, Ruvidar TM was successfully able to completely heal the HSV-1 lesions in an animal model; whereas, neither Abreva (10% Docosanol) nor Acyclovir (5%) were able to completely heal them. A very interesting observation from this experiment is that Ruvidar TM (1%) was able to completely heal the HSV-1 lesions at a fraction of the dose of the other two FDA approved drugs and completed this task with an application frequency of only once per day versus 5 times daily. My next set of experiments, in conjunction with my colleagues, and Dr. Mandel will be to optimize the formulation that will be analyzed in GLP toxicology, as well as clinically evaluated in a Phase I, II and III clinical study.' Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, " The preclinical data is what I would have predicted based on my previous research into this versatile drug; Ruvidar TM (1%) is superior in efficacy, when directly compared to two FDA-approved drugs; specifically: Acyclovir (5%) and Abreva (10% Docosanol). As one of the potential Mechanisms Of Action ('MOA'), it is well established in the literature that the glycoproteins of the HSV-1 virus (glycans—gB and gC) are negatively charged, as is the Heparan Sulphate ('HS') receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus. 3,4 On the other hand, Ruvidar TM is positively charged. 5 This allows Ruvidar TM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. The Theralase® research team is currently investigating additional MOAs to explain the ability of Ruvidar TM to effectively inactivate HSV-1 and to stop the progression of cold sore lesions in their tracks. ' Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, " I am delighted with the research team's latest set of experiments demonstrating the superiority of Ruvidar TM in the effective destruction of HSV-1 lesions versus Acyclovir (5%) and Abreva (10% Docosanol). Based on the success of this latest preclinical research, Theralase® will commence formulation of Ruvidar TM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of Ruvidar TM in the accelerated healing of cold sore lesions in humans. ' About Herpes Simplex: Herpes Simplex Virus ('HSV'), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable. 1 There are two main types of HSV: 1 Type 1 ('HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ('HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes. 1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033. 2 References: 1 Herpes simplex virus 2 3 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 2023 4 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578. 5 Ruvidar (TM) Enhances Efficacy of Cancer Drug About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
Yahoo
10-04-2025
- Health
- Yahoo
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 ("HSV-1") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. On Day 1 post-infection, these mice were treated with either: Acyclovir (5%), Abreva (10% Docosanol) or RuvidarTM (1%). Figure 1. Acyclovir (5%) (5 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit: Figure 2. Abreva (10% Docosanol) (6 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit: Figure 3. RuvidarTM (1%) (5 days of treatment x once per day)To view an enhanced version of this graphic, please visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., Research Scientist, Theralase®, who conducted the preclinical study stated, "I have now had the opportunity to conduct my next set of experiments, where I increased the number of daily applications of Acyclovir (5%) and Abreva (10% Docosanol) from once per day to 5 times daily for 5 and 6 days, respectively. In this set of experiments, RuvidarTM (1%) remained at once daily for 5 days. As can be clearly seen from the photographs, RuvidarTM was successfully able to completely heal the HSV-1 lesions in an animal model; whereas, neither Abreva (10% Docosanol) nor Acyclovir (5%) were able to completely heal them. A very interesting observation from this experiment is that RuvidarTM (1%) was able to completely heal the HSV-1 lesions at a fraction of the dose of the other two FDA approved drugs and completed this task with an application frequency of only once per day versus 5 times daily. My next set of experiments, in conjunction with my colleagues, and Dr. Mandel will be to optimize the formulation that will be analyzed in GLP toxicology, as well as clinically evaluated in a Phase I, II and III clinical study." Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, "The preclinical data is what I would have predicted based on my previous research into this versatile drug; RuvidarTM (1%) is superior in efficacy, when directly compared to two FDA-approved drugs; specifically: Acyclovir (5%) and Abreva (10% Docosanol). As one of the potential Mechanisms Of Action ("MOA"), it is well established in the literature that the glycoproteins of the HSV-1 virus (glycans—gB and gC) are negatively charged, as is the Heparan Sulphate ("HS") receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus.3,4 On the other hand, RuvidarTM is positively charged.5 This allows RuvidarTM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. The Theralase® research team is currently investigating additional MOAs to explain the ability of RuvidarTM to effectively inactivate HSV-1 and to stop the progression of cold sore lesions in their tracks." Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, "I am delighted with the research team's latest set of experiments demonstrating the superiority of RuvidarTM in the effective destruction of HSV-1 lesions versus Acyclovir (5%) and Abreva (10% Docosanol). Based on the success of this latest preclinical research, Theralase® will commence formulation of RuvidarTM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of RuvidarTM in the accelerated healing of cold sore lesions in humans." About Herpes Simplex:Herpes Simplex Virus ("HSV"), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable.1 There are two main types of HSV:1 Type 1 ("HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ("HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes.1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033.2 References:1 Herpes simplex virus2 Herpes Simplex Virus Treatment Market Size, Top Share, Key Developments | By 20333 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 20234 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578.5 Ruvidar(TM) Enhances Efficacy of Cancer Drug About Theralase® Technologies Inc.:Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements:This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
24-03-2025
- Health
- Associated Press
Ruvidar Effective in the Treatment of Herpes
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Ruvidar TM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 ('HSV-1") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model. Herpes Simplex Virus ('HSV'), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable. 1 There are two main types of HSV: 1 Type 1 ('HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ('HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes. 1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033. 2 The market growth can be attributed to the growing concerns over HSV infection, including, oral and genital herpes. Moreover, the infection is highly contagious, spreading via saliva, vaginal secretion or semen and is acquired unknowingly. These factors highlight the increasing need for treatment throughout the projected period. 3 North America accounted for the largest market share of 37.1% in 2024, which can be attributed to higher consumption of branded herpes drugs, escalating healthcare expenditure, increasing launch of generics and favorable reimbursement policies. 2 The HSV-1 lifecycle begins upon contact with mucosal surfaces and it is in this niche, where the virus actively replicates inducing local lesion formation. The virus then enters local sensory nerve endings and migrates back to neuronal cell bodies in the peripheral nervous system. It is in this location where the virus enters into a latent, non-replicative stage until later reactivation. 4 Despite longstanding attempts at therapy and prevention, HSV remains among the most prevalent human infectious viral pathogens; therefore, it's imperative to keep HSV from replicating by implementing advanced vaccines and more effective drugs to combat and defeat this pervasive disease. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. TM (1%). Figure 2. Abreva treatment of HSV-1 infected cutaneous lesions To view an enhanced version of this graphic, please visit: Acyclovir (1%) Treatment [ This image cannot be displayed. Please visit the source: ] Figure 3. Acyclovir (1%) treatment of HSV-1 infected cutaneous lesions Cannot view this image? Visit: Ruvidar TM (1%) Treatment [ This image cannot be displayed. Please visit the source: ] Figure 4. Ruvidar TM (1%) treatment of HSV-1 infected cutaneous lesions Cannot view this image? Visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., research scientist, Theralase®, who conducted the preclinical study stated, " I am extremely impressed with the efficacy of the Ruvidar TM to successfully heal the HSV-1 lesions in an animal model versus common standard of care treatments, currently available, such as Abreva and Acyclovir. My next set of experiments will be to increase the number of daily applications of Abreva, Acyclovir and Ruvidar TM (from once daily to 5 times daily) and increase the dosage of Acyclovir and Ruvidar TM (1 to 5%) to see how this affects the healing time of HSV-1 lesions. It is my hope that my preclinical research leads to the development of a clinical treatment to aid the multitude of individuals suffering from cold sores.' Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, " Based on the chemical properties of Ruvidar TM, I am not surprised that it has had such a dramatic effect on the inactivation of HSV-1 lesions in this animal model. It is well established in the literature that the HSV-1 virus' glycoproteins (glycans - gB and gC) are negatively charged, as is the Heparan Sulphate ('HS') receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus. 5,6 On the other hand, Ruvidar TM is positively charged. 7 This allows Ruvidar TM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. ' Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, " As always, I am in awe of the ability of Ruvidar TM to effectively destroy cancer cells, as well as efficiently inactivate bacteria and viruses. Based on the success of this latest preclinical research, Theralase®, pending funding in 2025, will commence formulation of Ruvidar TM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of Ruvidar TM in the accelerated healing of cold sore lesions in humans. ' 1 2 3 Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030 Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030 4 Roizman B, Knipe DM, Whitley R. Herpes Simplex Viruses. 6th ed. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. pp. 1823-1897. 5 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 2023 6 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578. 7 About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. (5273)
Yahoo
24-03-2025
- Health
- Yahoo
Ruvidar Effective in the Treatment of Herpes
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 ("HSV-1") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model. Herpes Simplex Virus ("HSV"), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable.1 There are two main types of HSV:1 Type 1 ("HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1. Type 2 ("HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual. An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes.1 The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033.2 The market growth can be attributed to the growing concerns over HSV infection, including, oral and genital herpes. Moreover, the infection is highly contagious, spreading via saliva, vaginal secretion or semen and is acquired unknowingly. These factors highlight the increasing need for treatment throughout the projected period.3 North America accounted for the largest market share of 37.1% in 2024, which can be attributed to higher consumption of branded herpes drugs, escalating healthcare expenditure, increasing launch of generics and favorable reimbursement policies.2 The HSV-1 lifecycle begins upon contact with mucosal surfaces and it is in this niche, where the virus actively replicates inducing local lesion formation. The virus then enters local sensory nerve endings and migrates back to neuronal cell bodies in the peripheral nervous system. It is in this location where the virus enters into a latent, non-replicative stage until later reactivation.4 Despite longstanding attempts at therapy and prevention, HSV remains among the most prevalent human infectious viral pathogens; therefore, it's imperative to keep HSV from replicating by implementing advanced vaccines and more effective drugs to combat and defeat this pervasive disease. In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. On Day 1 post-infection, these mice were treated once daily for 5 days with either: No Treatment, Abreva (a common over the counter treatment), Acyclovir (1%) or RuvidarTM (1%). No Treatment Figure 1. No treatment of HSV-1 infected cutaneous lesionsTo view an enhanced version of this graphic, please visit: Abreva Treatment Figure 2. Abreva treatment of HSV-1 infected cutaneous lesionsTo view an enhanced version of this graphic, please visit: Acyclovir (1%) Treatment Figure 3. Acyclovir (1%) treatment of HSV-1 infected cutaneous lesionsCannot view this image? Visit: RuvidarTM (1%) Treatment Figure 4. RuvidarTM (1%) treatment of HSV-1 infected cutaneous lesionsCannot view this image? Visit: The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model. Pavel Kaspler, Ph.D., research scientist, Theralase®, who conducted the preclinical study stated, "I am extremely impressed with the efficacy of the RuvidarTM to successfully heal the HSV-1 lesions in an animal model versus common standard of care treatments, currently available, such as Abreva and Acyclovir. My next set of experiments will be to increase the number of daily applications of Abreva, Acyclovir and RuvidarTM (from once daily to 5 times daily) and increase the dosage of Acyclovir and RuvidarTM (1 to 5%) to see how this affects the healing time of HSV-1 lesions. It is my hope that my preclinical research leads to the development of a clinical treatment to aid the multitude of individuals suffering from cold sores." Arkady Mandel, M.D., Ph.D., Chief Scientific Officer, Theralase® stated, "Based on the chemical properties of RuvidarTM, I am not surprised that it has had such a dramatic effect on the inactivation of HSV-1 lesions in this animal model. It is well established in the literature that the HSV-1 virus' glycoproteins (glycans - gB and gC) are negatively charged, as is the Heparan Sulphate ("HS") receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus.5,6 On the other hand, RuvidarTM is positively charged.7 This allows RuvidarTM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions." Roger DuMoulin-White, President and Chief Executive Officer, Theralase® stated, "As always, I am in awe of the ability of RuvidarTM to effectively destroy cancer cells, as well as efficiently inactivate bacteria and viruses. Based on the success of this latest preclinical research, Theralase®, pending funding in 2025, will commence formulation of RuvidarTM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of RuvidarTM in the accelerated healing of cold sore lesions in humans." References:1 Herpes simplex virus2 Herpes Simplex Virus Treatment Market Size, Top Share, Key Developments | By 20333 Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 20304 Roizman B, Knipe DM, Whitley R. Herpes Simplex Viruses. 6th ed. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. pp. 1823-1897.5 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 20236 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578.7 Ruvidar(TM) Enhances Efficacy of Cancer Drug About Theralase® Technologies Inc.:Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements:This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit Sign in to access your portfolio
New York Times
25-02-2025
- Health
- New York Times
Can You Get Rid of Cold Sores for Good?
Q: I get cold sores several times a year. Is there a way to keep them from coming back? It usually starts with a tingling at the edge of your lip. Painful, fluid-filled bumps emerge. Then they pop, ooze, scab over and eventually heal. Every few months, this cycle repeats. Cold sores, also known as fever blisters, can develop after infection with the herpes virus. (They're commonly caused by a version of the virus called herpes simplex virus type 1, or HSV-1, which is different from the version that typically causes genital herpes). For many, the lesions are 'unsightly and painful,' said Dr. Christine Johnston, a professor of infectious diseases at the University of Washington School of Medicine. They're also common, she added: Roughly half of people in the United States have HSV-1. Here's how to treat cold sores, and whether you can prevent them. What causes cold sores? The herpes virus is 'very contagious,' said Dr. Dean Blumberg, chief of pediatric infectious diseases at UC Davis Health. You can pick it up through close contact with someone who is infected, such as through kissing or sharing food or drinks. And it's not always easy to tell whether someone is contagious, Dr. Blumberg said. People can transmit oral herpes without a visible cold sore. If you do become infected, you might not develop a cold sore right away or even at all, Dr. Blumberg added. It could take years before you have an outbreak, Dr. Johnston said, or maybe you never get one. Once you start getting cold sores, however, the virus can cause outbreaks throughout your life. The frequency varies from person to person, Dr. Johnston said; some people get one cold sore a year, others get them multiple times a year. What's the best way to treat cold sores? Most cold sores will resolve on their own in about a week, Dr. Blumberg said. But doctors usually recommend that patients take a prescription oral antiviral medication, such as acyclovir, valacyclovir or famciclovir. Antiviral medications are very effective, Dr. Blumberg said. And taking them as early as possible — at the first sign of tingling or sensitivity around your mouth, for example — can decrease the pain and shorten the time for healing, Dr. Johnston added. Sometimes, she said, it might prevent the bump from forming at all. If you get six or more cold sores per year, your doctor may recommend something called suppressive antiviral therapy, which involves taking an antiviral medication every day to reduce the number, severity and length of outbreaks. This therapy may also reduce your chances of spreading the virus to others. Many over-the-counter topical treatments — such as those containing the active ingredient docosanol (Abreva) — claim to heal cold sores quickly, sometimes in as few as 2.5 days. But the doctors we spoke with didn't recommend them. Topical medications are less effective than oral antiviral medications because they don't penetrate into the nerve cells where the virus lives, so they can't 'address the root cause' of outbreaks by stopping the herpes virus from replicating, said Dr. Cindy Wassef, a dermatologist at the Robert Wood Johnson University Hospital in Somerset, N.J. Topical medications also don't heal the sores as quickly as oral antivirals, Dr. Johnston added. But some over-the-counter products can help reduce pain while cold sores heal. These include steroid and numbing creams, Dr. Wassef said, and pain relievers like acetaminophen and aspirin, Dr. Blumberg added. It's also helpful to avoid consuming anything acidic, like citrus or vinegar, which can make cold sores sting, Dr. Blumberg said. Cold drinks, ice pops and ice cream, on the other hand, can help soothe the pain. Can you cure cold sores? While individual cold sore episodes will heal, there's no way to banish the virus from your body, so you'll always be at risk for future outbreaks, Dr. Wassef said. 'HSV-1 is a chronic infection,' Dr. Johnston added. 'Right now, there is no cure.' However if you know that your outbreaks are prompted by certain triggers, like exposure to ultraviolet light, for example, you could try avoiding that trigger, such as by wearing sunscreen or lip balm with an S.P.F. of at least 30, Dr. Blumberg said. Scientists have been working on a herpes vaccine, which Dr. Johnston said is still early in the research and testing phase. Most of the work has been done on genital herpes, more commonly caused by the herpes simplex virus type 2, she explained, but 'hopefully, once we get a breakthrough there, we could then study it in cold sores.' Researchers are also looking into therapies that alter the DNA of the virus in your body. In a 2024 study, scientists injected mice with gene editing molecules. This removed 90 percent of the herpes virus involved in cold sores (and 97 percent of the virus involved in genital herpes). The authors concluded that gene editing could potentially contribute to a cure for oral and genital herpes, but more research is needed. For now, the only way to prevent cold sores is to avoid contracting the herpes virus in the first place — but that's practically impossible for many people, Dr. Johnston said. 'It's a very ubiquitous virus.'
